NCT02518958View on ClinicalTrials.gov

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 21, 2015

Primary Completion Date

May 17, 2016

Study Completion Date

September 12, 2016

Conditions
Malignant Solid TumorLymphoma
Interventions
DRUG

RRx-001

DRUG

Nivolumab

Trial Locations (1)

20889

Walter Reed National Military Medical Center, Bethesda

Sponsors

Lead Sponsor

EpicentRx, Inc.
All Listed Sponsors
lead

EpicentRx, Inc.

INDUSTRY